24341-72-8 Usage
Uses
Used in Pharmaceutical Research:
3-[(Thien-2-ylcarbonyl)amino]benzoic acid is used as a research compound for studying its potential as a drug target in the development of new medications. Its unique structure and properties make it a promising candidate for further investigation in medicine.
Used in Cancer Research:
In the field of cancer research, 3-[(Thien-2-ylcarbonyl)amino]benzoic acid is used as a potential drug target for the treatment of various types of cancer. Its specific chemical structure allows for the exploration of its interactions with biological systems and its potential to inhibit or modulate cancer-related pathways.
Used in Drug Development:
3-[(Thien-2-ylcarbonyl)amino]benzoic acid is utilized in drug development as a starting point for the synthesis of new pharmaceutical agents. Its heterocyclic nature and functional groups provide opportunities for chemical modifications and optimization to enhance its therapeutic potential.
Used in Medicinal Chemistry:
In medicinal chemistry, 3-[(Thien-2-ylcarbonyl)amino]benzoic acid serves as a valuable building block for the design and synthesis of novel compounds with potential therapeutic applications. Its unique structural features can be exploited to create new molecules with improved pharmacological properties.
Used in Chemical Synthesis:
3-[(Thien-2-ylcarbonyl)amino]benzoic acid is used as a key intermediate in the synthesis of various organic compounds and pharmaceuticals. Its reactivity and functional groups make it a versatile component in the preparation of complex molecules for research and development purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 24341-72-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,3,4 and 1 respectively; the second part has 2 digits, 7 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 24341-72:
(7*2)+(6*4)+(5*3)+(4*4)+(3*1)+(2*7)+(1*2)=88
88 % 10 = 8
So 24341-72-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H9NO3S/c14-11(10-5-2-6-17-10)13-9-4-1-3-8(7-9)12(15)16/h1-7H,(H,13,14)(H,15,16)
24341-72-8Relevant academic research and scientific papers
Selective butyrylcholine esterase inhibitor or pharmaceutically acceptable salt thereof, and preparation method and application thereof
-
Paragraph 0037-0039, (2020/01/12)
The invention discloses a selective butyrylcholine esterase inhibitor represented by a general formula (I) or a pharmaceutically acceptable salt thereof, and a preparation method and an application thereof. Butyrylcholine esterase inhibitory activity, sel
3-acylamino-N-arylbenzamide compound as well as preparation and application thereof
-
Paragraph 0030, (2018/12/14)
The invention provides a 3-acylamino-N-arylbenzamide compound and pharmaceutically acceptable salt thereof. The synthesis of the compound is divided into different synthetic blocks by adopting a convergent synthetic route and a target compound can be quickly prepared in batches through docking combination. The experiment proves that the compound provided by the invention has the advantages that the epileptic seizure latency induced by pentylenetetrazol can be significantly prolonged and the grade and mortality rate of epileptic seizures are reduced; a threshold of epileptic seizure induced bymaximum electroshock can be significantly increased and the mortality rate is reduced; in addition, a seizure threshold of refractory epilepsy can be obviously increased; besides, no obvious toxic orside effects are found, which indicates that the 3-acylamino-N-arylbenzamide compound can relieve or control epileptic seizures or even has a certain therapeutic effect on the refractory epilepsy which cannot be effectively treated by traditional drugs, so that the compound can be applied to the preparation of antiepileptic drugs. The compound disclosed by the invention has the advantages of easily-obtained raw materials for synthesizing, simple operation, high process scalability, suitability for industrial production and capability of providing a novel drug for epilepsy treatment. The structure of a general formula I is shown in the description.
